General Information of Drug (ID: DM7QE51)

Drug Name
I-309 Drug Info
Synonyms
2050-48-8; bis(4-bromophenyl)sulfone; 4,4'-Sulfonylbis(bromobenzene); Bis(p-bromophenyl) sulfone; Sulfone, bis(p-bromophenyl); 4-Bromophenyl sulfone; 4,4'-Dibromodiphenyl sulfone; 1,1'-sulfonylbis(4-bromobenzene); 4,4'-Dibromodiphenylsulfone; Benzene, 1,1'-sulfonylbis[4-bromo-; 4,4'-DIBROMO DIPHENYL SULFONE; Bis(p-bromophenyl)sulfone; Benzene, 1,1'-sulfonylbis(4-bromo-; NSC 43047; BRN 2505841; 1-bromo-4-(4-bromophenyl)sulfonylbenzene; AI3-22602; AK112394; 1-bromo-4-(4-bromophenyl)sulfonyl-benzene
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
95927
CAS Number
CAS 2050-48-8
TTD Drug ID
DM7QE51

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-1811 DMCEMC6 Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
CCX-832 DMD8QHV Psoriasis vulgaris EA90 Discontinued in Phase 1 [4]
viral macrophage inflammatory protein-II DMAXOPS Discovery agent N.A. Investigative [5]
ZK 756326 DMP089G Discovery agent N.A. Investigative [6]
N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide DMQS9OH Discovery agent N.A. Investigative [7]
N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide DM74KHG Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 8 (CCR8) TTE836A CCR8_HUMAN Binder [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 812).
2 The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51.
3 Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology. 2022 Nov 4;11(1):2141007.
4 Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877.
5 HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74.
6 Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16.
7 Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84.